Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Dec 12, 2008

Premium
TcLand Expression, a spin-out of the French research institute INSERM/ITERT that focuses on gene expression biomarkers in immunology, has appointed Alessandra Cervino as vice president of bioinformatics and biostatistics, and Patrick Larcier, as vice president of clinical and regulatory affairs.
 
Cervino will manage the statistical and bioinformatics teams. Previous to TcLand Expression, she was head of statistical sciences and assistant professor at Scripps Florida, where she conducted a genome-wide study of lupus and developed a workflow to combine genotypic and transcriptomic data to identify novel genes.
 
She was group leader in statistical genetics at Rosetta/Merck, where she worked to translate genetic research programs into new drug targets and pharmacogenetic programs. She holds a PhD in clinical medicine from the University of Oxford.
 
Larcier will run clinical and regulatory operations, and will be responsible for the global relationship with regulatory agencies. Before joining the firm, he was vice president of drug development at Neovacs, an antibody-therapy company, and associate director of international regulatory affairs at Biogen.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.